| Name | Title | Contact Details |
|---|---|---|
Jon Miller |
Chief Technology Officer (CTO) | Profile |
NCD is dedicated to improving lives by driving better health, providing an exceptional experience, and Spreading the Smile. As the costs of dental and vision insurance continue to increase across the country, our mission is to provide comprehensive dental and vision care thats accessible, quick to obtain, and simple to use. Whether youre uninsured or under-insured, NCD has a plan that fits your dental and vision needs.
Specializing in post-acquisition integration and restructuring, achieving operational excellence, supporting buyers like private equity firms with due diligence and deal dynamics, as well as coaching and development.
McBride Consulting, LLC, is a minority and Service-Disabled Veteran-Owned Small Business (SDVOSB) management consulting and project management firm with significant professional services experience that includes business strategy development, finance, accounting and audit readiness support, information security controls, business process optimization, human capital management and operations.
The BIG3 is the premier league for 3v3 hoops. Featuring many of the worlds most popular and accomplished athletes.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.